Editorial: Safety and Effects of Direct Oral Anticoagulants for Portal Vein Thrombosis

医学 门静脉血栓形成 肝硬化 腹水 门脉高压 经颈静脉肝内门体分流术 胃肠道出血 肝移植 门静脉压 血栓形成 凝血病 血栓 外科 内科学 移植
作者
Nina Kimer,Lise Hobolth,Lise Lotte Gluud
出处
期刊:Alimentary Pharmacology & Therapeutics [Wiley]
标识
DOI:10.1111/apt.18512
摘要

Portal vein thrombosis (PVT) is a serious complication in chronic liver disease, mainly occurring in patients with portal hypertension [1]. The pathophysiology of PVT includes a combination of venous stasis, hypercoagulability and endothelial dysfunction, leading to reduced portal flow velocity and stagnation of blood in the splanchnic circulation [2, 3]. PVT is associated with a range of complications in cirrhosis, including variceal bleeding and ascites and PVT may become a contraindication for liver transplantation [4]. Many cases are asymptomatic and detected incidentally during routine imaging. Symptomatic presentations include abdominal pain, worsening ascites or gastrointestinal bleeding. Treatment aims at achieving recanalisation with anticoagulation [5]. The safety of anticoagulation in cirrhosis requires consideration, especially in those with coagulopathy or varices. Acute-on-chronic PVT involves thrombus formation superimposed on a background of long-standing partial obstruction, often presenting more subtly but with potential for worsening liver function. PVT in people without cirrhosis is mainly acute and often due to an acquired or inherited prothrombotic condition [5, 6]. Although treatment principles are similar, non-cirrhotic cases generally have fewer risks related to coagulopathy, altering the safety and efficacy profile of anticoagulation therapy. In a study of 102 patients with acute PVT without cirrhosis, recanalisation of the portal vein was achieved in 39% following anticoagulation with vitamin K antagonists (VKA) and nine experienced gastrointestinal bleeding [6]. Treating PVT with direct oral anticoagulants (DOACs) offers several advantages over VKA including a more predictable effect eliminating the need for frequent monitoring. In a meta-analysis of 10 observational studies and one randomised trial including patients with cirrhosis and PVT, DOACs were associated with recanalisation in 87% [7]. Premkumar et al. report their experience with dabigatran for benign PVT [8]. The rate of recanalisation was assessed for 72 patients with cirrhosis and 47 without cirrhosis receiving dabigatran. Comparison groups consisted of 28 patients (18 with cirrhosis) who declined treatment and six patients with CP > 10 who received VKA. Recanalisation occurred in 56 (47.1%) patients treated with dabigatran and more frequently in acute compared to acute-on-chronic PVT. The large proportion of patients with acute on chronic PVT may partly explain the relatively low number of patients who achieved recanalisation. A large number of patients were identified through screening for portal hypertension rather than based on symptoms or incidental findings, which may impact results. None of the patients treated with VKA and 6 (21.4%) without treatment experienced spontaneous recanalisation. The overall adverse event rate of dabigatran was 6.7% including one patient with variceal bleeding and three with epistaxis [8]. This aligns with the result of a meta-analysis comparing anticoagulants versus no anticoagulation where 4% in the treatment group experienced variceal bleeding and 11% experienced major bleeding episodes [7]. Although the non-randomised design and the heterogeneity of patients should be considered when making conclusions, the overall result is very promising. The evidence suggests that DOACs are considered for the treatment of PVT, especially in patients with acute PVT. Additional evidence is needed to evaluate the benefit–risk ratio in patients with decompensated cirrhosis and in patients with acute on chronic PVT. Nina Kimer: writing – review and editing. Lise Hobolth: writing – review and editing. Lise Lotte Gluud: conceptualization, writing – original draft, writing – review and editing. N.K. and L.H. declare no conflicts of interest. L.L.G.: Novo Nordisk, Pfizer, Becton Dickinson, Gilead, Sobi, Alexion, Astra Zeneca, Boehringer Ingelheim, Immunovia and Norgine. This article is linked to Premkumar et al paper. To view this article, visit https://doi.org/10.1111/apt.18474. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小鱼儿发布了新的文献求助10
刚刚
2秒前
2秒前
wjx发布了新的文献求助10
2秒前
3秒前
3秒前
3秒前
3秒前
KK完成签到 ,获得积分10
3秒前
吴14完成签到,获得积分10
3秒前
涛涛发布了新的文献求助10
3秒前
xin发布了新的文献求助10
5秒前
C1nderella发布了新的文献求助10
5秒前
xiao发布了新的文献求助10
6秒前
完美世界的应助被xiaowu采纳,获得10
6秒前
我要攒积分完成签到 ,获得积分10
7秒前
7秒前
云1辰发布了新的文献求助10
7秒前
7秒前
XIXI发布了新的文献求助20
7秒前
7秒前
充电宝的应助被Rita采纳,获得10
8秒前
8秒前
8秒前
miya完成签到 ,获得积分10
8秒前
wanci的应助被ne采纳,获得10
8秒前
9秒前
Carmen发布了新的文献求助10
10秒前
10秒前
跳跃问蕊发布了新的文献求助10
11秒前
Danny完成签到,获得积分10
11秒前
和谐幻桃发布了新的文献求助10
11秒前
11秒前
深情安青的应助被jiaqiao采纳,获得10
12秒前
高贵烧鹅发布了新的文献求助10
12秒前
丁盼来发布了新的文献求助10
12秒前
13秒前
传奇3的应助被zyl采纳,获得10
13秒前
i坤发布了新的文献求助10
14秒前
前进四19完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8156113
求助须知:如何正确求助?哪些是违规求助? 9552375
关于积分的说明 21709417
捐赠科研通 7745230
什么是DOI,文献DOI怎么找? 3426391
关于科研通互助平台的介绍 2551314
邀请新用户注册赠送积分活动 2470141